Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.79 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.67 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15267524 | 1.00 | PPARG (0.79) | PPARGSLC22A12PPARAP2RY1PTGER4 | |
| SCHEMBL18174524 | 1.00 | PPARG (0.79) | PPARGSLC22A12PPARAP2RY1PTGER4 | |
| Mbx-102 Acid Form SCHEMBL12189837 | 0.88 | PPARG (1.00) | PPARGSLC22A12PPARAP2RY1PTGER4 | |
| SCHEMBL2450141 | 0.88 | PPARG (0.81) | PPARGSLC22A12PPARAP2RY1PTGER4 | |
| Metaglidasen SCHEMBL14606136 | 0.88 | PPARG (1.00) | PPARGSLC22A12PPARAP2RY1PTGER4 | |
| SCHEMBL18174880 | 0.88 | PPARG (0.61) | PPARGSLC22A12PPARAP2RY1KDM4E | |
| SCHEMBL12189841 | 0.88 | PPARG (0.81) | PPARGSLC22A12PPARAP2RY1PTGER4 | |
| SCHEMBL15267987 | 0.88 | PPARG (0.61) | PPARGSLC22A12PPARAP2RY1KDM4E | |
| SCHEMBL18174879 | 0.88 | PPARG (0.61) | PPARGSLC22A12PPARAP2RY1KDM4E | |
| Metaglidasen SCHEMBL29387584 | 0.88 | PPARG (1.00) | PPARGSLC22A12PPARAP2RY1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073345-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES | ALAPATI MOHAN MURALI (IN) | 2017-03-16 | — | — | US | disclosed |
| WO-2016181199-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF UREA CYCLE DISORDERS AND GOUT | MOHAN M ALAPATI (IN) | 2016-11-17 | — | — | WO | disclosed |
| US-9475747-B1 | Compositions and methods for the treatment of urea cycle disorders and gout | ALAPATI MOHAN MURALI (IN) | 2016-10-25 | — | — | US | disclosed |
| US-9475747-B1 | Compositions and methods for the treatment of urea cycle disorders and gout | ALAPATI MOHAN MURALI (IN) | 2016-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073345-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES | DPP4, SLC5A1, SLC5A2 | PPARG 404/4885SLC22A12 788/4885PPARA 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.